# PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
Canonical URL: https://biopharmsignal.com/news/PYPD/polypid-receives-pdufa-fee-waiver-from-fda-for-d-plex-s-new-drug-application
Ticker: PYPD
Company: PolyPid
Source: PolyPid
Published: 2026-03-17 12:30 EST
Original Source URL: https://investors.polypid.com
## Summary

FDA  Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of th is Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative

## Article Body
FDA  Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of th is Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative
## Recent Company News
- 2026-06-01 12:30 EST — [PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀](https://biopharmsignal.com/news/PYPD/polypid-completes-new-drug-application-submission-to-fda-for-d-plex) — Source: PolyPid
- 2026-05-20 12:30 EST — [PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference](https://biopharmsignal.com/news/PYPD/polypid-to-participate-in-the-craig-hallum-23rd-annual-institutional-investor-conference) — Source: PolyPid
- 2026-05-13 11:30 EST — [PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: PolyPid
- 2026-05-06 12:00 EST — [PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026](https://biopharmsignal.com/news/PYPD/polypid-to-report-first-quarter-2026-financial-results-and-operational-highlights-on-may-13-2026) — Source: PolyPid
- 2026-04-28 12:30 EST — [PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting](https://biopharmsignal.com/news/PYPD/polypid-to-present-data-from-shield-ii-phase-3-trial-demonstrating-reduced-severity-of-surgical-site-infection-at-surgical-infection-society-2026-annual-meeting) — Source: PolyPid
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)